ORKA Filings — Oruka Therapeutics, Inc. - FilingSpy
ORKA
Oruka Therapeutics, Inc.
A clinical-stage biotech developing longer-lasting antibody drugs for skin conditions like psoriasis, aiming for injections that may be needed only once or twice a year. Its lead candidates, ORKA-001 and ORKA-002, come from Paragon Therapeutics, a drug-discovery engine that also spawned other biotechs. The name blends Hebrew words for "skin" and "restoration," and the company went public in 2024 through a reverse merger with ARCA biopharma, trading as "ORKA."
Select a row to see that insider’s individual transactions. † Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: +1.32M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.